Cowen And Company, LLC Exelixis, Inc. Call Options Transaction History

Cowen And Company, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 12, 2024	BUY	$21.96 - $27.6 $329,400 - $414,000	15,000 New	15,000 $389,000
Q1 2024 May 03, 2024	BUY	$20.17 - $23.93 $1.67 Million - $1.99 Million	83,000 New	83,000 $1.97 Million
Q3 2023 Nov 09, 2023	BUY	$19.04 - $22.74 $104,720 - $125,069	5,500 New	5,500 $120,000
Q3 2021 Nov 12, 2021	SELL	$16.3 - $21.14 $448,250 - $581,350	-27,500 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$17.95 - $25.56 $493,625 - $702,900	27,500 New	27,500 $8,000
Q1 2021 May 04, 2021	SELL	$20.53 - $25.22 $307,950 - $378,300	-15,000 Closed	0 $0
Q4 2020 Feb 08, 2021	BUY	$18.39 - $24.8 $275,850 - $372,000	15,000 New	15,000 $8,000

502

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Cowen And Company, LLC with notifications on news.